Mortality benefit of statin use in traumatic spinal cord injury: A retrospective analysis

Abstract

Study design:An observational study based on retrospective review of the medical charts and death records of 163 individuals with traumatic spinal cord injuries (SCI).Objectives:To determine whether HMG coA Reductase Inhibitor ('statin') use in a cohort of patients with traumatic SCI reduced overall and cause-specific mortality.Setting:An outpatient clinic designated for veterans with SCI at the Oklahoma City Veterans Administration Hospital.Methods:Review and analysis of the medical records of 163 veterans with traumatic SCI cared for between the years 2000 and 2014. Data collected included statin use, duration of statin use and intensity of statin therapy, as well as cause-specific mortality.Results:Seventy five participants had taken statins for an average of 5.7±3.7 years, and had greater cardiovascular risk burdens than those who had not taken statins (n=88). Statin use was associated with a reduced risk of death. The mortality rate for those patients on statins was 33.8-49.9 per 1000 person-years, depending on assumptions made regarding residual effects of statin use. Under most assumptions this was significantly lower than the mortality rate seen in those not on statins (47.4-66.8 deaths per 1000 person-years). Within the statin group, neither duration nor average intensity of statin therapy affected mortality.Conclusion:Statin use among a cohort of veterans with traumatic SCI reduced all-cause mortality. This retrospective study ought to spur further investigations into the potential benefits of statin use among people with chronic SCI, and begin a discussion as to whether individuals with injuries should routinely be offered statin therapy.